On December 1, 2021 GlyTherix reported the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams (Press release, Glytherix, DEC 1, 2021, View Source [SID1234596313]). Funds will be used to generate new preclinical models to evaluate the efficacy, biodistribution, and pharmacokinetics of our lead cancer immunotherapy antibody, Miltuximab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent installation of start-of-the-art PET-CT and SPECT-CT imaging systems at ANSTO will facilitate high-resolution small animal imaging of Miltuximab.

The theranostic products produced and tested in this project will generate significant input for the design of our Phase Ib trial to ensure that safety and efficacy endpoints will be met with confidence.

Dr Brad Walsh, CEO GlyTherix, commented "We are extremely grateful to the NSW Government for their continued support of our important therapeutic program, particularly as we have a first-in-world radio-immunotherapy developed in NSW. Additionally, we are pleased that this strengthens our long collaboration with ANSTO who have partnered with us in developing this radioimmunotherapy. A win-win for NSW companies."